Oncotarget

Research Papers:

High uric acid (UA) downregulates bone alkaline phosphatase (BALP) expression through inhibition of its promoter activity

Zhi-Qi Wu, Xiao-Ting Chen, Yan-Yan Xu, Ming-Jie Tian, Hai-Yan Chen, Guo-Ping Zhou and Hua-Guo Xu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:85670-85679. https://doi.org/10.18632/oncotarget.21110

Metrics: PDF 1627 views  |   HTML 2144 views  |   ?  


Abstract

Zhi-Qi Wu1,*, Xiao-Ting Chen1,*, Yan-Yan Xu2,*, Ming-Jie Tian1, Hai-Yan Chen1, Guo-Ping Zhou2 and Hua-Guo Xu1

1Department of Laboratory Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China

2Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China

*These authors contributed equally to this work

Correspondence to:

Hua-Guo Xu, email: huaguoxu@njmu.edu.cn

Keywords: bone alkaline phosphatase, uric acid, promoter, bone metastasis

Received: August 02, 2017     Accepted: September 03, 2017     Published: September 20, 2017

ABSTRACT

Bone metastases often occur in prostate cancers, lung cancers and breast cancers. Bone alkaline phosphatase (BALP) is one of the most commonly used serological markers for clinical evaluation of bone metabolism. Here, we reported that high concentrations of uric acid (UA) caused decrease of BALP levels and revealed that the effect of high concentrations of UA on the BALP expression was through inhibition of its promoter activity. Our results suggested physicians to think about serum UA status of patients with advanced cancer to avoid misdiagnosis when BALP was used to diagnose or assess the extent of bone metastases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21110